Overview
SLN market data
Price History
SLN price chart · 1M
- O
- 13.56
- H
- 13.60
- L
- 13.36
- C
- 13.53
- Vol
- 20,659.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $13.56
- Previous Close
- $13.66
- Day High
- $13.60
- Day Low
- $13.36
- 52 Week High
- $17.51
- 52 Week Low
- $4.75
- 7 Day Return
- -0.55%
- 30 Day Return
- +11.68%
- 90 Day Return
- +96.87%
- 1 Year Return
- +117.09%
- Daily Notional Volume
- $279.4K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.53 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.68 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -8,943.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.06 – $5.99 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $641.6M · P/B 3.53 · P/S 764.73.
Company News
Reported Earlier, Silence Therapeutics Prices Upsized $175M Underwritten Public Offering Of 12,962,963 ADSs At $13.50 Per ADSBenzinga · Aug 12, 2026, 6:58 AM
Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $32Benzinga · Aug 11, 2026, 3:52 PM
Silence Therapeutics Announces Commencement Of Approximately $150M Underwritten Public Offering Of American Depositary SharesBenzinga · Aug 10, 2026, 8:04 PM
Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'Benzinga · Aug 10, 2026, 2:15 PM
Varex Imaging Posts Upbeat Q3 Earnings, Joins Bowman Consulting, MarineMax And Other Big Stocks Moving Higher On MondayBenzinga · Aug 10, 2026, 2:11 PM
Silence Therapeutics shares are trading higher after the company announced topline results from the Phase 2 SANRECO trial met its primary and secondary endpoints.Benzinga · Aug 10, 2026, 1:08 PM
12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga · Aug 10, 2026, 12:06 PM
Silence Therapeutics Says Phase 2 SANRECO Trial Of Divesiran In Polycythemia Vera Met Primary Endpoint, 88% Response Rate vs. 19% For Placebo; Phase 3 Seen Starting 1H 2027Benzinga · Aug 10, 2026, 11:33 AM
Silence Therapeutics Q2 EPS $(0.09) Beats $(0.15) EstimateBenzinga · Aug 10, 2026, 11:22 AM
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving PremarketBenzinga · Aug 10, 2026, 8:59 AM